<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="69224">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02204644</url>
  </required_header>
  <id_info>
    <org_study_id>HS-10096-301</org_study_id>
    <nct_id>NCT02204644</nct_id>
  </id_info>
  <brief_title>The Study of the Efficacy and the Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With CML</brief_title>
  <official_title>Randomized, Multi-center, Open-label Phase III Study of the Efficacy and Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Hansoh Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Hansoh Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to observe the efficacy and the safety of Flumatinib vs Imatinib as first line
      treatment in patients with newly diagnosed chronic phase chronic myelogenous leukemia.

      Randomized,Open Label,Control
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SIX-month major molecular response rate</measure>
    <time_frame>six months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>major molecular response rate</measure>
    <time_frame>3 months, 9 months and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">480</enrollment>
  <condition>CML, CML-CP,MMR,TKI</condition>
  <arm_group>
    <arm_group_label>Flumatinib mesylate tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Flumatinib mesylate tablets 600mg qd for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Imatinib mesylate tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Imatinib mesylate tablets 400mg qd for 12months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flumatinib 600mg qd</intervention_name>
    <arm_group_label>Flumatinib mesylate tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib 400mg qd</intervention_name>
    <arm_group_label>Imatinib mesylate tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women aged 18-75 year-old

          2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2

          3. Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph +
             CP-CML) within 6 months of diagnosis

          4. Adequate organ function

        Exclusion Criteria:

          1. received TKIs drug treatment before enrollment

          2. Central nervous system leukemia

          3. Previous anti-CML therapy over two weeks (hydroxyurea, except anagrelide) or surgery
             (including hematopoietic stem cell transplantation)

          4. Cardiac dysfunction

          5. Previous splenectomy

          6. History of congenital or acquired bleeding disorders unrelated to CML

          7. Previous malignancy except CML

          8. Acute or chronic liver or severe kidney disease unrelated to CML

          9. Pregnant, breastfeeding, child bearing potential but failed to take effective
             contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital of Blood Diseases, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Zhang</last_name>
      <phone>+86 22 23909120</phone>
    </contact>
    <investigator>
      <last_name>Jianxiang Wang, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <lastchanged_date>July 27, 2015</lastchanged_date>
  <firstreceived_date>July 29, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
